Multiple Sclerosis and Neuroimmunology Clinical Trials

Project BIG: The Stanford Brain Immune Gut Research Initiative
Status: Active, Enrolling
PI: Jeffery Dunn, MD
Research Coordinators:  Viktoriya Bourakova and Lila Perrone
Contact: viktoriya.bourakova@stanford.edu, perronel@stanford.edu

North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) Study
PI: Jeffery Dunn, MD
Study Status: Enrolling
Research Coordinator: Viktoriya Bourakova
Contact: viktoriya.bourakova@stanford.edu

A Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif ®) in Patients with Relapsing Multiple Sclerosis
PI: Jeffery Dunn, MD
NCT01412333
Study Status: Closed to Enrollment
Research Coordinator: Yamuna Joseph

Multicenter, Randomized, Double-Blind, Parallel-Group Extension to Study AC-058B201 to Investigate the Long-Term Safety, Tolerability, and Efficacy of 10, 20, and 40 mg/day ACT-128800, an Oral S1P1 Receptor Agonist, in Patients with Relapsing-Remitting Multiple Sclerosis
PI: Jeffery Dunn, MD
NCT01093326
Study Status: Closed to Enrollment
Research Coordinator: Yamuna Joseph

A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects with Relapsing-Remitting Multiple Sclerosis Switching from Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment (101MS329)
PI: Lucas Kipp, MD
NCT03689972
Study Status: Closed to Enrollment
Research Coordinator: Lila Perrone

 A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Progressive Forms of Multiple Sclerosis (M14-397)
PI: Christopher Lock, MD
NCT03737812
Study Status: Closed to Enrollment
Research Coordinator: Lila Perrone

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis (M18-918)
PI: Christopher Lock, MD
NCT03737851
Study Status: Closed to Enrollment
Research Coordinator: Lila Perrone

1A Phase 2, Open-label, Multicenter study to evaluate the safety and efficacy of repeated administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors; MSC-NTF cells) in participants with Progressive Multiple Sclerosis (MS) (BCT-101-US)
PI: Christopher Lock, MD
NCT03799718
Study Status: Enrolling
Research Coordinator: Viktoriya Bourakova
Contact: viktoriya.bourakova@stanford.edu

A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-Remitting Multiple Sclerosis (MNK14274069)
PI: Christopher Lock, MD
NCT03126760
Study Status: Enrolling
Research Coordinator: Yamuna Joseph
Contact: yamuna@stanford.edu

An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis
PI: Christopher Lock, MD
NCT02688985
Study Status: Closed to Enrollment
Research Coordinator: Yamuna Joseph

A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
PI: Christopher Lock, MD
NCT02792218
Study Status: Closed to Enrollment
Research Coordinator: Yamuna Joseph

A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)
PI: Christopher Lock, MD
NCT03277261
Study Status: Closed to Enrollment
Research Coordinator: Yamuna Joseph

Neuroimmunology Clinical Trials Contact

Yamuna Joseph
Clinical Research Coordinator
Department of Neurosurgery and Neurology
Stanford University School of Medicine
Office: (650) 497-6810
Cell: (650) 529-5524
Fax: (650) 721-5113